Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368867 | PMC |
| http://dx.doi.org/10.3389/fphar.2024.1473052 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in Drug Safety: Highlights from the 23rd Annual Meeting of the International Society of Pharmacovigilance.
Drug Saf
December 2024
North American Chapter of the International Society of Pharmacovigilance, Cambridge, USA.
Antipsychotics or Mood Stabilizers in Bipolar Disorder: Towards Evidence-Based Personalised Medicine.
Acta Psychiatr Scand
December 2024
University of Bordeaux, Inserm U1219 Bordeaux Population Health Research Centre, Bordeaux, France.
Cannabis combined with oxycodone for pain relief in fibromyalgia pain: a randomized clinical self-titration trial with focus on adverse events.
Front Pain Res (Lausanne)
November 2024
Tackling and Preventing the Opioid Epidemic (TAPTOE) Consortium, Utrecht, Netherlands.
Objectives: We determined whether adding cannabis to oxycodone for chronic non-cancer pain management could reduce treatment-related adverse effects (AEs) while maintaining effective analgesia.
Methods: In this open-label study, fibromyalgia patients aged ≥18 years were randomized to receive 5 mg oxycodone tablets (max. four times/day), 150 mg of inhaled cannabis containing 6.
Oral Corticosteroid-Related Healthcare Resource Utilization and Associated Costs in Patients with COPD.
Adv Ther
November 2024
Observational and Pragmatic Research Institute, Singapore, Singapore.
Article Synopsis
- Oral corticosteroids (OCS) are commonly used to manage exacerbations of chronic obstructive pulmonary disease (COPD) but can lead to negative health outcomes that increase healthcare costs and resource use.
- A study analyzed data from the UK Clinical Practice Research Datalink to compare healthcare attendance and costs between COPD patients who used OCS and those who didn’t, focusing on hospital visits and costs.
- Results showed that patients who used OCS had significantly higher healthcare attendance and costs, with the increases correlating positively with the cumulative OCS dose, particularly for primary care consultations and emergency visits.
Well-Conducted Real-World Evidence Studies Can Complement Essential Evidence From Clinical Trials.
Circulation
October 2024
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!